Lin TL et al. Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: a population-based cohort study. J Am Acad Dermatol. 2024(24)00788-6. û收藏 2 评论 ñ1 ...
Atopic dermatitis (AD) is a common childhood disease that can lead to considerable burden in children and downstream effects including decreased sleep quality, self image, and school performance.1 In children already managing complex medical conditions, the addition of burdensome and often distressing ...
原文标题:Dupilumab Improves Clinical Scores in Pediatric Patients Aged 2 to <18 Years with Uncontrolled Atopic Dermatitis: A Single-Center, Real-World Study 译文标题:Dupilumab改善了2至<18岁…
“Atopic dermatitis (AD) is a chronic pruritic and inflammatory disease that is highly prevalent in both adult and pediatric patients and requires long-term treatment; thus, safety is an important consideration for physicians and patients/caregivers when making decisions on treatment options,” La...
Dupilumab in pediatric dermatology. PMID: 32602761 Dupilumab: A review of its use in the treatment of atopic dermatitis. PMID: 29471919 Cutaneous T-cell lymphoma following dupilumab use: a systematic review. PMID: 36073768 Dupilumab progressively improves systemic and cutaneous abnormalities in patients ...
Dupilumab effective for atopic dermatitis in young children with, without comorbidities Infants and young children with atopic dermatitis experienced improvements in signs and symptoms with dupilumab treatment regardless of other type 2 comorbidities, according to a study published in Advances in Therapy. ...
Adult and Pediatric Dosage Forms and Strengths Solution for Injection 300 mg/2mL 200 mg/1.14mL Available as a single-dose prefilled syringe Dosage Considerations – Should be Given as Follows: Moderate-to-Severe Atopic Dermatitis Indicated whendermatitisis not adequately controlled with topical prescri...
Dupilumabis an anti-IL-4receptor antagonist, preventing the function of both IL-4 and IL-13 in the type 2 inflammation cascade (Fig. 1).Dupilumabwas first registered in the treatment of moderate-to-severeatopic dermatitis. In 2018 the indication for severeeosinophilicasthma was added. Dupilumab...
The final child had developed unrecognized psoriasis that was revealed when their concomitant severe atopic dermatitis responded to dupilumab. The Methods Paller and colleagues utitlized the medical records of pediatric patients who developed psoriasiform lesions while using the biologic. All the data ...
Atopic Dermatitis:DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be use...